Satellos Switches BASECAMP Primary Endpoint to MRI Fat Fraction After FDA Feedback
MSLE is trading near its 52-week low of $5.44 (10% above the low) on elevated volume (2.9× avg).
Summary
Following FDA feedback, Satellos changed BASECAMP's primary endpoint to MRI-measured muscle fat fraction, a measure it says could support accelerated approval. Topline 12-week data is still expected in Q1 2027.
Key Events · Product Development and Regulatory · MSLE
-
Primary Endpoint Switched to MRI Fat Fraction
Following FDA feedback, BASECAMP's primary efficacy endpoint changes from dynamometry to change in MRI-measured vastus lateralis fat fraction; a protocol amendment has been submitted.
-
Possible Accelerated Approval Path
According to Satellos, fat fraction plus clinical endpoints may serve as a surrogate reasonably likely to predict clinical benefit, which could support an accelerated approval pathway for forazapadin.
-
TRAILHEAD Supports the Measure
In the open-label adult TRAILHEAD study, forazapadin produced a mean 3.7 percentage-point reduction in biceps brachii fat fraction, from 49.7% at baseline to 46.0% at Day 140.
-
Topline Data Still Q1 2027
The 12-week placebo-controlled BASECAMP topline readout remains expected in Q1 2027, consistent with the delay disclosed on 2026-09-30; the trial enrolls 53 ambulatory boys aged 7-9.
Analysis · MSLE · Life Sciences
This is a regulatory-strategy pivot, not a cosmetic tweak: the 53-patient BASECAMP Phase 2 trial is moving its primary endpoint from dynamometry to MRI-measured vastus lateralis fat fraction. Fat fraction is an objective measure tied to disease progression, and management says it could serve as a surrogate reasonably likely to predict clinical benefit — the basis for an accelerated approval. That raises the stakes on the Q1 2027 topline readout. A positive result on this measure could support a faster path to market for forazapadin; a miss would hit a trial whose endpoint was just redefined. Supporting TRAILHEAD data — a mean 3.7 percentage-point fat-fraction reduction, from 49.7% to 46.0% at Day 140 — is early-stage adult evidence, not pediatric proof.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MSLE was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.7M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.